AtriCure (ATRC) PT Raised to $26 at Needham & Company Amid NEJM Trial

Needham & Company analyst Mike Matson reiterated a Buy rating and boosted his price target on AtriCure Inc. (NASDAQ: ATRC) to $26.00 (from $21.00) after the NEJM trial shows surgical ablation reduces atrial fibrillation.

Matson commented, "A randomized controlled trial (RCT) was published in The New England Journal of Medicine (NEJM) comparing ablation to no ablation in patients with atrial fibrillation (AF) having mitral valve surgery. The trial showed: 1) ablation resulted in a significantly greater reduction in AF; 2) there was no difference in pulmonary vein isolation (PVI) and biatrial maze (maze) ablation AF rates; and 3) the ablation group had a higher rate of permanent pacemakers. Given its rigorous design and publication in NEJM, we expect this trial to help drive increased use of surgical ablation."

For an analyst ratings summary and ratings history on AtriCure Inc. click here. For more ratings news on AtriCure Inc. click here.

Shares of AtriCure Inc. closed at $20.50 yesterday.

You May Also Be Interested In

• MarineMax (HZO) PT Lowered to $35 at Stifel
• First Cash Financial (FCFS) PT Lowered to $140 at TD Cowen
• Bristol-Myers Squibb Co. (BMY) PT Lowered to $64 at Truist Securities